Annual report [Section 13 and 15(d), not S-K Item 405]

License Agreements (Details)

v3.25.1
License Agreements (Details) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 30, 2015
May 11, 2015
May 31, 2016
Mar. 31, 2015
Dec. 31, 2024
Dec. 31, 2023
Feb. 28, 2023
Jan. 31, 2019
License Agreements                
Issuance of common shares - Founders Agreement         $ 995,000 $ 952,000    
NeuPharma, Inc.                
License Agreements                
Payment of upfront licensing fees       $ 1,000,000        
NeuPharma, Inc. | Additional sales milestone                
License Agreements                
Maximum potential milestone payments       40,000,000        
NeuPharma, Inc. | Clinical and development milestone                
License Agreements                
Maximum potential milestone payments       39,000,000        
NeuPharma, Inc. | Regulatory approvals to commercialize the products                
License Agreements                
Maximum potential milestone payments       22,500,000        
Dana-Farber Cancer Institute                
License Agreements                
Payment of upfront licensing fees       $ 1,000,000        
Issuance of common shares - Founders Agreement (in shares) 13,683 50,000            
Issuance of common shares - Founders Agreement $ 600,000 $ 32,500            
Purchase price per share   $ 0.65            
Ownership percentage       5.00%        
Cash in exchange for common shares       $ 10,000,000        
Amount of milestone expensed         5,000,000      
Maintenance fee       50,000        
Dana-Farber Cancer Institute | First commercial sale milestone                
License Agreements                
Maximum potential milestone payments       21,500,000        
Dana-Farber Cancer Institute | Additional sales milestone                
License Agreements                
Maximum potential milestone payments       $ 60,000,000        
Adimab, LLC | PD-L1                
License Agreements                
Non-Refundable milestone payment             $ 2,200,000  
Adimab, LLC | Regulatory approvals to commercialize the products                
License Agreements                
Maximum potential milestone payments               $ 2,500,000
Jubilant Biosys Limited                
License Agreements                
Payment of upfront licensing fees     $ 2,000,000          
Jubilant Biosys Limited | Clinical and development milestone                
License Agreements                
Maximum potential milestone payments     88,400,000          
Jubilant Biosys Limited | Regulatory approvals to commercialize the products                
License Agreements                
Maximum potential milestone payments     59,500,000          
Jubilant Biosys Limited | Sale Millstone                
License Agreements                
Maximum potential milestone payments     $ 89,300,000          
Collaboration Agreement With TGTX                
License Agreements                
Revenue recognition milestone revenue recognized         $ 41,000 $ 58,000    
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]         Revenues Revenues    
Sublicense Agreement with TGTX                
License Agreements                
Revenue recognition milestone revenue recognized         $ 46,000